Drug Type Small molecule drug |
Synonyms MY-008, MY008, MY008211A |
Target |
Mechanism CFB inhibitors(Complement factor B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hemoglobinuria, Paroxysmal | Phase 2 | CN | 06 Jul 2023 | |
Glomerulonephritis, IGA | Phase 2 | - | - | |
C3 glomerulopathy | IND Approval | CN | 18 Dec 2023 | |
Diabetic Nephropathies | IND Approval | CN | 18 Dec 2023 | |
Idiopathic Membranous Glomerulonephritis | IND Approval | CN | 18 Dec 2023 | |
Lupus Nephritis | IND Approval | CN | 18 Dec 2023 |